Early-Bird Discount For PharmAsia Summit Expires Aug. 31
As pharma looks to broaden its capabilities beyond its four walls and spread the risk and rewards of drug development, companies are looking east to the multi-billion dollar Asian market, especially emerging markets like China and India. Read more...
Hear China & India Case Studies From Industry Leaders
Already many biopharma companies are taking advantage of Asia’s scientific talent pool and large patient base to outsource R&D and clinical trials, and to develop unique alliances with local companies and universities to speed up drug development. With the global economic crisis upon us, and major pharma industry challenges like the approaching patent cliff, these R&D trends are likely to accelerate in coming years.
But speeding up development is just one reason multinationals want to build a presence in Asia. The other reason: emerging markets like China and India are the fastest growing markets for pharmaceuticals, with some experts forecasting growth of 14-15 percent in 2009, compared to 1-2 percent growth in the U.S.Yet regulatory, reimbursement and commercial challenges in these markets are considerable, and major changes are on the horizon, including Chin health care reform and the move toward a central India regulatory authority modeled after U.S. FDA.
To get the latest developments on these Asia emerging markets, join Windhover and PharmAsia News for three days of interactive discussions, case studies and panels, and capitalize on Asia's booming pharmaceutical market. Confirmed speakers include:
**WuXi Apptec CEO Ge Li
**Hutchison Pharma CEO Samantha Du
**Former FDA Commissioner Andrew von Eschenbach
**Sanofi-Aventis China R&D Head Frank Jiang
**Roche China R&D Chief Scientific Officer Li Chen
**Eli Lilly Global R&D China Site Head Tony Zhang
And many more! Join us in San Francisco Oct. 26-28. To cash in on the early-bird discount, register before Aug. 31.
